04 | 12 - 15 | 2021

ANGIODYNAMICS

The 20th Annual Needham Virtual Healthcare Conference

Jim Clemmer, President & CEO Stephen Trowbridge, EVP & CFO



Forward-Looking Statement

Notice Regarding Forward-LookingStatements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "projects," "believes," "seeks," "estimates," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics' expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics' technology or assertions that AngioDynamics' technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate acquired businesses, as well as the risk fact

In the United States, the NanoKnife System has received a 510(k) clearance by the Food and Drug Administration for use in the surgical ablation of soft tissue, and is similarly approved for commercialization in Canada, the European Union and Australia. The NanoKnife System has not been cleared for the treatment or therapy of a specific disease or condition.

Notice Regarding Non-GAAP Financial Measures

Management uses non-GAAP measures to establish operational goals and believes that non-GAAP measures may assist investors in analyzing the underlying trends in AngioDynamics' business over time. Investors should consider these non-GAAP measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with GAAP. In this presentation, AngioDynamics' has reported adjusted EBITDA (income before interest, taxes, depreciation and amortization and stock-based compensation); adjusted net income and adjusted earnings per share. Management uses these measures in its internal analysis and review of operational performance. Management believes that these measures provide investors with useful information in comparing AngioDynamics' performance over different periods. By using these non-GAAP measures, management believes that investors get a better picture of the performance of AngioDynamics' underlying business. Management encourages investors to review AngioDynamics' financial results prepared in accordance with GAAP to understand AngioDynamics' performance taking into account all relevant factors, including those that may only occur from time to time but have a material impact on AngioDynamics' financial results. Please see the tables that follow for a reconciliation of non-GAAP measures prepared in accordance with GAAP.



ANGIODYNAMICS

Strategic Transformation





PURSUIT OF LARGER MARKETS

Active portfolio management enables us to compete in larger, growing markets relying on technology & innovation to produce measurable patient outcomes

FOCUSED RESOURCE DEVELOPMENT

Resource deployment is focused in areas that offer best opportunities for success

PORTFOLIO TRANSFORMATION


Portfolio transformation & strength is driven by R&D, M&A, and Clinical & Regulatory

TOP TALENT

Portfolio combined with talent drives value

FOCUSED TRANSFORMATION

U.S. Total Addressable Markets



INVEST FOR GROWTH

Peripheral Atherectomy

Thrombus Management AngioVac Uni-Fuse⁺

Irreversible Electroporation







MAINTAIN POSITIONING

Vascular Access Catheters and Accessories

Diagnostic Catheters, Guidewires and Kits

Endovenous Laser Treatment

Microwave & Radiofrequency Tumor Ablation

Lung Biopsy Safety

Radiation Treatment Stabilization Balloons

FOCUSED INVESTMENT



Leveraging 3 main drivers to carve out our space in large, growing markets through innovative, disruptive technologies that treat patients with cancer, promote healthy blood flow and deliver critical therapies.




04 | 12 - 15 | 2021

PERIPHERAL ATHERECTOMY







CONTRACTOR OFFICENCE

Aspiration and Off-Center capabilities and indicated for Peripheral Atherectomy and In-Stent Restenosis (ISR)

2.0 mm

Aspiration capability and indicated for Peripheral Atherectomy and ISR **1.5 mm** Indicated for




0.9 mm Indicated for Peripheral Atherectomy

Why wavelength matters

Each type of tissue interacts differently with a given wavelength The Auryon System produces a photon energy of 3.5 eV, which is low enough to be nonreactive to vessel endothelium, but high enough to vaporize calcium. ^{b, c}

Why pulse width and amplitude matter

Greater amplitude is achieved with shorter pulses, which can deposit energy before thermal diffusion occurs The Auryon System has a pulse width of 10 to 25 ns, ensuring enough power to target the lesion and spare the vessel. ^a




a. Auryon, Instructions for use. AngioDynamics; 2019. b. Herzog A, Bogdan S, Glikson M, Ishaaya AA, Love C. Selective tissue ablation using laser radiation at 355 nm in lead extraction by a hybrid catheter a preliminary report. Lasers Surg Med. 2016;48(3):281-287. c. Spectranetics Corporation. CVX-300 Extimer Laser System: Operator's Manual. Version 28. 2019:1-56.

PERIPHERAL ATHERECTOMY

US Addressable Markets & Competitive Landscape

Company	Product	Thrombus	Plaque	Fibrotic	ISR	Calcified
ANGO	Auryon	***	***	**	***	**
Philips	Excimer Laser	**	**		***	*
MDT	TurboHawk		***	*		*
BSC	Jetstream	**	*	*		
CSI	Diamonback 360		**	*		***

angiodynamics



1. Peripheral Vascular Devices Medtech 360 Market Analysis US 2017. (2016, December). Millennium Research Group, Inc.

PERIPHERAL ATHERECTOMY

Continuing our momentum of growth

COMMERCIAL SCALE

- Targeted commercial & clinical expansion
- Meaningful physician training programs
- Increase physician ambassador programs

M

CLINICAL COMPENDIUM

- Expand awareness by creating a strong podium and clinical publication presence
- Clinically differentiated validation through new users, data collection (PATHFINDER I & II), and clinical outcomes





PRODUCT DEVELOPMENT

- Product development pipeline
- Portfolio and product indication expansion
- Continuous voice of customer

04 | 12 - 15 | 2021


THROMBUS MANAGEMENTAngioVacUni-Fuse+





DVT & PE TREATMENT OPTIONS

Percutaneous Thrombectomy






Illustrations and Images not Produced by AngioDynamics Include: https://youtu.be/00UUBZ68x50 https://www.penumbrainc.com/indigo-liehtning/

THROMBUS MANAGEMENT

Purpose Built Portfolio & Technology



2. Fletcher Spaght, Inc. AngioVac market assessment March 2018, Angiodynamics funded



CURRENT PORTFOLIO

AngioVac's use is currently focused on the Right Atrium, which is a \$77M addressable market.

Planned Launch Calendar 2021

FUTURE PORTFOLIO

A multi-purpose mechanical aspiration device will allow us to compete in the broader DVT & PE addressable markets with a first-line treatment option without the need for perfusion.

CURRENT PORTFOLIO

DVT & PE

Uni-Fuse+ catheter directed thrombolysis now has the additional indication for placement in the pulmonary artery.

The AngioVac Difference


The AngioVac System allows for the **continuous aspiration** of embolic material such as fresh, soft thrombi or vegetation from the venous system

Utilizing a self-expanding, nitinol reinforced funnel tip

Simultaneously reinfusing the patient's own filtered blood to limit procedural blood loss







THE NEXT GENERATION OF ANGIOVAC

Physician requests for use in DVT drive new product development



THE NEXT PORTFOLIO INNOVATION

A purpose-built, innovative product leveraging the strengths of the AngioVac cannula technology with off-circuit manual aspiration control

Not approved by the Food and Drug Administration (FDA). These statements and the subject product have not been evaluated by the Food and Drug Administration (FDA). This product is not intended to diagnose, treat, cure, or prevent any disease. The device is not currently being marketed, nor is it available for sale in any country

Powerful

Proven, funnel tip design allows efficient aspiration and compression of large clot burden




Designed to allow the end-user command and control of the mechanical aspiration



Broadens our Thrombus Management portfolio and designed to provide an intuitive, first-line treatment option without the need for lytics and advanced procedural support

THROMBUS MANAGEMENT

Planned Portfolio Additions & U.S. Addressable Markets Expansion





The planned portfolio additions are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from AngioDynamics' expectations.

Purpose Built, Comprehensive, Thrombus Portfolio

Continuous Aspiration with Simultaneous Reinfusion AV3 | AV4 | C20 | C85 | C120

ALPHAVAC

AV3 AV4 C20 C85 C120

Uni-Fuse⁺

04 | 12 - 15 | 2021


IRREVERSIBLE ELECTROPORATION






IRREVERSIBLE ELECTROPORATION

Non-thermal energy destroys cells while preserving critical structures





Probe placement

Placement of probes around a target area provides effective treatment coverage ^{a-d}

Electrical field

Electrical pulses cause pores to form within the cellular membrane leading to nonthermal cell death ^{a-d}


Decellularization

Target tissue undergoes complete decellularization while preserving the underlying structure of blood vessels, nerves, ducts, and tissue ^{a-d}



Non-thermal

By preserving those underlying structures the potential for revascularization of treated tissue is maintained ^{a-d}



Revascularization


The NanoKnife System's unique technology enables physicians to provide localized treatments in locations and at times previously unavailable to them ^{a-d}



a. Maor E. et al., The effect of irreversible electroporation on blood vessels, Technol. Cancer Res. Treat. 6(4), 307–312 (2007).10.1177/153303460700600407.
b. Rubinsky, B., Onik, G., and Mikus, P., Irreversible electroporation: a new ablation modality-chincial implications. Technol. Cancer Res. Treat. 6, 37–48. (2007). doi:10.1177/153303460700600106.
c. Onik G., Mikus P., and Rubinsky B., Irreversible electroporation: inplications for prostate ablation, Technol. Cancer Res. Treat. 6(4), 295–300(207).10.1177/153303460700600405.
d. Lee EW, Chen C., Prieto VE, Dry SM, Loh CT, Kee ST., Advanced hepatic ablation technique for creating complete cell death: inversible electroporation. Radiology 255:426–433. (2010). doi:11.48/radiol.10090337

PROVIDES THE INNOVATION DOCTORS NEED


Expands treatment options and helps preserve patient's quality of life and



b. Rubinsky, B., Onik, G., and Mikus, P., Irreversible electroporation: anew ablation modality-clinical implications. Technol. Cancer Res. Treat. 6, 37–48. (2007). doi:10.1177/153303460700600106. c. Onik G., Mikus P., and Rubinsky B., Irreversible electroporation: implications for prostate ablation, Technol. Cancer Res. Treat. 6(4), 295–300(2007).10.1177/153303460700600405. d. Lee EW, Chen C, Prieto VE, Dry SM, Loh CT, Kee ST., Advanced hepatic ablation technique for creating complete cell death: irreversible electroporation. Radiology 255:426–433. (2010). doi:1148/radiol.10090337

NancKnife 3.0

New Cancer Cases 2020: 1,256,970^a






a. Cancer Facts & Figures 2020. American Cancer Society. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2020.html. Accessed January 7, 2021.



This study is evaluating the use of the NanoKnife System as a potential treatment for stage III pancreatic cancer.

Prostate IDE

This safety study will evaluate the use of the NanoKnife System as a focal therapy option for prostate tissue.





CLINICAL EXPANSION


Within the U.S. **191,930** men will be diagnosed with prostate cancer in 2020.[°]

27% will undergo radiotherapy of which **66%** report E.D. at 36 months

31% will undergo a radical prostatectomy of which **79%** report E.D. at 36 months_{b.c}

42% will undergo active surveillance

An estimated **38%** of these patients are ideal candidates for focal therapy



Focal therapy

bridges the gap between whole gland treatment and active surveillance in an attempt to maximize quality of life

by avoiding the effects of whole gland radiation or surgery.

However... adoption remains low (<5%) due to gaps within existing technology.



NANOKNIFE PLATFORM

Current Indications Surgical ablation of soft tissue



Expanding Indications

Pancreas pivotal study underway (DIRECT)

Prostate safety study underway

FDA Pre-Sub meeting regarding prostate tissue indication complete

≫

Expanded **Reimbursement**

Inpatient ICD-10 Code (2018) DRGs (2019)

Organ Agnostic CPT Code (2020)

Outpatient (2021) ASC (2021)





>>




VASCULAR ACCESS



VASCULAR ACCESS

Safely delivering medication to patients







PORTFOLIO

Delivering on our product road map including development of an integrated navigation & tip location technology that enables the use of our BioFlo PICC.

MARKET ACCESS

Maximize clinical differentiation by reducing thrombus accumulation through the utilization of our BioFlo family of catheters



Maintain a strong culture of execution and collaboration through disciplined sales & marketing plans

Q3 YTD FY2021 Highlights

Financial Performance

in millions (except per share data)	YTD FY2021	YTD FY2020	YOY Change
Revenue	\$214.2	\$205.8	4.1%
Gross Margin	53.4%	58.3%	(490 bps)
Net Loss	(\$12.1)	(\$9.7)	(\$2.4)
GAAP EPS	(\$0.32)	(\$0.26)	(\$0.06)
Adjusted EPS	\$0.05	\$0.15	(\$0.10)
Adjusted EBITDA	\$15.0	\$17.5	(\$2.5)
Free Cash Flow	\$7.3	(\$24.2)	\$31.5

Please see Appendix A for reconciliation of GAAP to Non-GAAP.

in millions	Q3 FY2021	Q4 FY2020	YOY Change
Cash	\$54.5	\$54.4	\$0.1
Debt	\$30.0	\$40.0	(\$10.0)

angiodynamics

Growth From Key Products

Key Product Categories	Q1 FY2021	Q2 FY2021	Q3 FY2021	YTD FY2021
AngioVac [®]	46%	24%	27%	31%
NanoKnife [®] Disposables	(5%)	30%	(7%)	4%
Auryon*	\$1.1	\$2.1	\$3.3	\$6.5

* Auryon reflects revenue contribution in quarter vs growth rate due to acquisition date in FY20.

ANGIODYNAMICS

Strategic Transformation





PURSUIT OF LARGER MARKETS

Active portfolio management enables us to compete in larger, growing markets relying on technology & innovation to produce measurable patient outcomes

FOCUSED RESOURCE DEVELOPMENT

Resource deployment is focused in areas that offer best opportunities for success

PORTFOLIO TRANSFORMATION

Portfolio transformation & strength is driven by R&D, M&A, and Clinical & Regulatory

TOP TALENT

Portfolio combined with talent drives value

04 | 12 - 15 | 2021

ANGIODYNAMICS

The 20th Annual Needham Virtual Healthcare Conference

Jim Clemmer, President & CEO Stephen Trowbridge, EVP & CFO



Appendix A



Reconciliation of GAAP to Non-GAAP Net Income and EPS

		Nine Months Ended					
(in thousands, except per share data)		b 28, 2021	Feb 29, 2020				
		(unau	dited	1)			
Net loss	\$	(12,080)	\$	(9,720)			
Amortization of intangibles		13,838		13,417			
Change in fair value of contingent consideration		(290)		116			
Acquisition, restructuring and other items, net (1)		3,057		4,486			
Write-off of deferred financing fees (2)		_		593			
Tax effect of non-GAAP items (3)	-	(2,606)		(3,205)			
Adjusted net income	\$	1,919	\$	5,687			
	Feb 28, 2021 (unau		dited				
	Fe	/		Feb 29, 2020			
				,			
Diluted loss per share	\$	(0.32)	\$	(0.26)			
Amortization of intangibles		0.36		0.35			
Change in fair value of contingent consideration		(0.01)					
Acquisition, restructuring and other items, net (1)		0.08		0.12			
Write-off of deferred financing fees (2)		_		0.02			
Tax effect of non-GAAP items (3)		(0.06)		(0.08)			
Tax effect of hon-of har items (5)							
Adjusted diluted earnings per share	\$	0.05	\$	0.15			
	\$	0.05	\$	0.15			

 Includes costs related to merger and acquisition activities, restructurings, and unusual items, including asset impairments and write-offs, certain litigation, and other items.

(2) Deferred financing fees related to the old credit agreement were written off during the second quarter of fiscal year 2020.

(3) Adjustment to reflect the income tax provision on a non-GAAP basis has been calculated assuming no valuation allowance on the Company's U.S. deferred tax assets and an effective tax rate of 23% for the periods ended February 28, 2021 and February 29, 2020.

(4) Diluted shares may differ for non-GAAP measures as compared to GAAP due to a GAAP loss.



Reconciliation of Net Loss to Adjusted EBITDA

	Nine Months Ended						
(in thousands)	Feb 28, 2021		Feb 29, 2020				
((unaudited)					
Net loss	\$	(12,080)	\$	(9,720)			
Income tax benefit		(2,033)		(1,506)			
Interest expense, net		676		672			
Depreciation and amortization		19,276		17,434			
Change in fair value of contingent consideration		(290)		116			
Stock based compensation		6,398		5,998			
Acquisition, restructuring and other items, net (1)		3,057		4,486			
Adjusted EBITDA	\$	15,004	\$	17,480			

 Includes costs related to merger and acquisition activities, restructurings, and unusual items, including asset impairments and write-offs, certain litigation, and other items.

Reconciliation of Free Cash Flow

	Nine Months Ended				
(in thousands)	Feb 28, 2021		Feb 29, 2020		
	(unaudited)				
Net cash provided by (used in) operating activities	\$	11,894	\$	(18,434)	
Additions to property, plant and equipment		(4,567)		(5,756)	
Free Cash Flow	\$	7,327	\$	(24,190)	